As genetic testing for breast cancer gene mutation expands, questions arise about treatment decisions
- Written by Katherine Drabiak, Assistant Professor of Bioethics and Genomics, University of South Florida
The Food and Drug Administration recently announced its authorization that permits genetics testing company 23andMe to market a test for gene mutations associated with risk of breast and ovarian cancer.
In response,...

